Inhibition by somatostatin (growth-hormone release-inhibiting hormone, GH-RIH) of gastric acid and pepsin and G-cell release of gastrin

A. A. J. BARROS D'SA,1 S. R. BLOOM, AND J. H. BARON2

From the Departments of Surgery and Medicine, Royal Postgraduate Medical School, London

SUMMARY Somatostatin (cyclic growth-hormone release-inhibiting hormone—GH-RIH) was infused into dogs with gastric fistulae. Somatostatin inhibited gastric acid response to four gastric stimulants—insulin, food, histamine, and pentagastrin. Histamine- and pentagastrin-stimulated pepsins were inhibited similarly to inhibition of acid. Somatostatin inhibited the gastrin response to insulin and food.

The cyclic hypothalamic tetradecapeptide, growth-hormone release-inhibiting hormone (GH-RIH), somatostatin, inhibits the secretion of growth hormone (Brazeau et al., 1973) and TSH (Hall et al., 1973) from the anterior pituitary, as well as insulin (Alberti et al., 1973) and glucagon (Mortimer et al., 1974) from the pancreas. More recently, somatostatin has been found markedly to suppress the release of gastrin in normal subjects (Bloom et al., 1974) and patients with the Zollinger-Ellison syndrome (Bloom et al., 1974, 1975). The first non-endocrine effects of somatostatin to be demonstrated were direct inhibition of gastric acid secretion in dogs (Barros D’Sa et al., 1975a) and of acid and pepsin in cats (Gomez-Pan et al., 1975). Similar inhibition by somatostatin of gastric acid and pepsin has been found in response to betazole in man (Lankisch et al., 1975), pentagastrin in man (Arnold and Creutzfeldt, 1975), and dog (Konturek et al., 1976) and in response to histamine, peptone, and urecholine in dogs (Konturek et al., 1976). Recent morphological studies have demonstrated somatostatin in the islet cells of the pancreas (Luft et al., 1974) and localised in the D cells of the pancreas, the stomach, and the duodenum (Polak et al., 1975).

In view of reported effects of somatostatin such as thrombocytopenia (Ricketts, 1975), impaired platelet aggregation (Besser et al., 1975; Goodner, 1975), with increased concentrations of the fibrin degradation product FgE in man (Lancet, 1975), we decided to perform further studies in dogs rather than in man. These experiments were designed to test the effects of somatostatin on gastric acid, gastrin and pepsin in response to insulin hypoglycaemia, a meat meal, histamine, and pentagastrin.

Methods

Four trained dogs (25-30 kg) with previously fashioned gastric fistulae were studied after an overnight fast. Blood samples were drawn from a venous catheter and 0·9% saline or somatostatin infusion given into a superficial leg vein. Pure synthetic cyclic somatostatin was used (Baychem Ltd) and was infused in 0·9% saline in concentrations in the range 0·5-32 μg/kg·h.

During histamine and pentagastrin-stimulated experiments somatostatin was infused in the second hour of a three hour infusion of submaximal doses of histamine acid phosphate (0·5 μg/kg·min) and pentagastrin (1 μg/kg·h). In the insulin experiments insulin 0·2 u/kg was given as a single intravenous injection, and somatostatin (5 or 8 μg/kg·h) infused for 30 minutes before and 90-120 minutes after the insulin injection. Fifteen minute collections of gastric juice were made and the volume and titratable acidity (to pH 7) were measured. Pepsin concentration was measured by an Autoanalyzer method (Vatier et al., 1968) using haemoglobin as a substrate (Anson and Mirsky, 1932). Blood samples were also taken every 15 minutes for measurements of plasma glucose and gastrin. Glucose was measured by the glucose oxidase method of Wincey and Marks (1961) adapted for an Autoanalyzer. Plasma immunoreactive gastrin was measured by radioimmunoassay

1Present address: Singleton Hospital, Swansea.
2Address for correspondence: Dr J. H. Baron, Department of Surgery, Royal Postgraduate Medical School, Hammersmith Hospital, London, W12 0HS.

Received for publication 14 November 1977
(Russell et al., 1976) using antiserum Gas 8 which is sensitive to changes in human G-17 of 1.5 pmol/l, reacts 50% with G34, but has no affinity for pentagastrin or big bi gastrin.

During meal-stimulated experiments somatostatin was given intravenously in the first two hours of a three hour experiment and acid output was measured by the technique of intragastric titration with sodium bicarbonate (Fordtran and Walsh, 1973) modified for the dog (Barros D'Sa et al., 1975b). The meal consisted of Lassie meat (20 g/kg). Plasma gastrins were also measured.

**Results (Table)**

**INSULIN**

Dogs 1 and 2 were infused with 8 μg/kg-h somatostatin (Fig. 1) and dogs 3 and 4 with 5 μg/kg-h (Fig. 2). The mean degree of hypoglycaemia after insulin during the control infusion of saline was not significantly different from that seen after insulin during somatostatin infusion and there was no observable difference in the behaviour of the dogs on the two occasions. The mean gastrin increment was inhibited by 70% after the lower dose and 86% after the higher dose of somatostatin, almost identical with the inhibition of insulin-stimulated acid output of 74% and 85% after these doses.

**MEAL (Fig. 3)**

Inhibition of acid output was greater with increasing doses of somatostatin. With the lowest dose of 0.5 μg/kg-h there was a rebound in secretion after the somatostatin infusion was stopped, with the acid output exceeding control levels. During the two-hour infusion with higher doses of 1 μg/kg-h, gastric acid was totally inhibited in every dog with some return of secretion after stopping the infusion. Acid secretion was completely inhibited throughout the three hours with the other four doses, 2, 4, 8 and 16 μg/kg-h. The inhibition by somatostatin of meal-stimulated gastrin was also dose dependent (Fig. 4).

**Table**  **Percentage inhibition of acid, pepsin, and gastrin by somatostatin**

<table>
<thead>
<tr>
<th>Stimulant</th>
<th>Mean percentage inhibition after somatostatin (dose μg/kg-h)</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>0.5</td>
</tr>
<tr>
<td>Acid output</td>
<td></td>
</tr>
<tr>
<td>Insulin</td>
<td>71*</td>
</tr>
<tr>
<td>Meal</td>
<td></td>
</tr>
<tr>
<td>Histamine</td>
<td>42*</td>
</tr>
<tr>
<td>Pentagastrin</td>
<td></td>
</tr>
<tr>
<td>Pepsin output</td>
<td></td>
</tr>
<tr>
<td>Histamine</td>
<td>72*</td>
</tr>
<tr>
<td>Pentagastrin</td>
<td></td>
</tr>
<tr>
<td>Gastrin rise</td>
<td></td>
</tr>
<tr>
<td>Insulin</td>
<td>0*</td>
</tr>
<tr>
<td>Meal</td>
<td>0*</td>
</tr>
</tbody>
</table>

Comparisons have been made for histamine and pentagastrin between the 30 minutes before somatostatin compared with the second half hour of the somatostatin infusion, for meals between the fourth half hour of somatostatin and control, and after insulin between the 90 minutes of somatostatin infusion and control. The superscripts indicate the number of experiments. The mean percentage inhibition by somatostatin 4 μg/kg-h represents the pooled results from doses of 4 and 5 μg/kg-h.
Inhibition by somatostatin of gastric acid and pepsin and G-cell release of gastrin

In all experiments except when the lowest dose of somatostatin was used there was a marked depression in plasma gastrin levels with a definite rise after the somatostatin infusion was stopped. The recovery phase of gastrin after stopping somatostatin was also dose dependent, with the least recovery with higher doses of somatostatin.

Pepsin data are difficult to interpret because of the initial washout rise of pepsin after histamine followed by a fall and rise. Pepsin outputs after somatostatin were inhibited less than acid outputs (Table).

**HISTAMINE**

Acid output was depressed by somatostatin in histamine experiments (Fig. 5).

**PENTAGASTRIN**

Pentagastrin-stimulated acid output decreased immediately and rapidly after somatostatin was infused (Fig. 6). Acid output was reduced by 94% and pepsin output reduced by 76%. There was some recovery in acid output and marked recovery in pepsin output after the somatostatin infusion was stopped.

**Basal plasma gastrin**

This was not affected by the infusions of histamine or pentagastrin. During the somatostatin infusion these still basal plasma levels were depressed with some recovery after the somatostatin infusions were stopped (Figs. 5 and 6).

**Discussion**

In these experiments somatostatin inhibited the secretion of the parietal cells in response to insulin,
Fig. 4  Inhibition by GH-RIH of meal-stimulated plasma gastrin. In this and subsequent graphs ▲—▼ indicates GH-RIH 2 μg/kg-h and ■ —■ 16 μg/kg-h.

Fig. 5  Inhibition by GH-RIH of histamine-stimulated plasma gastrin and gastric acid and pepsin output. ▵ — ▼ indicates GH-RIH 32 μg/kg-h.

Fig. 6  Inhibition by GH-RIH, 16 μg/kg-h, of penta-gastrin-stimulated plasma gastrin and gastric acid and pepsin output.
Inhibition by somatostatin of gastric acid and pepsin and G-cell release of gastrin

meals, histamine, and pentagastrin, and inhibited the release of gastrin from the G-cells both under basal conditions and in response to insulin and to a meal. In the insulin studies a comparable degree of hypoglycaemic stimulus was attained in the control and test experiments, so that somatostatin’s inhibition of insulin-stimulated gastric secretion must have been due to inhibition of the release of gastrin from G-cells, and/or an effect on the parietal cells to gastrin and/or direct vagal cholinergic stimuli.

The present studies have established in dogs that somatostatin inhibits gastrin release in response both to vagal stimulation and food as in normal man after a meal (Bloom et al., 1974), and in hypergastrinaemic patients with pernicious anaemia and a gastrinoma (Bloom et al., 1974).

The relationship of gastrin release to gastric acid secretion after hypoglycaemia is complex (Cowley et al., 1973). In man the peak plasma gastrin after insulin hypoglycaemia precedes the peak acid output by 15 to 30 minutes (Cowley et al., 1973) and a similar delay was seen in dogs (Figs. 1 and 2), suggesting that the vagally released gastrin could indirectly prime the parietal cells to respond to direct cholinergic vagal stimulation.

In the meal experiments there was a tendency for gastric acid and plasma gastrin to rebound after the infusions of low doses of somatostatin were stopped. In the histamine, insulin, and pentagastrin experiments there was some recovery in acid output after the inhibitory influence of somatostatin was lost but there was no rebound (Gomez-Pan et al., 1975), nor has a rebound rise been seen in the hormone secretion of patients with hormone secreting tumours after stopping somatostatin (Mortimer et al., 1974; Bloom et al., 1974).

Histamine- and pentagastrin-stimulated pepsin was inhibited by somatostatin to a similar degree as inhibition of acid. Inhibition by somatostatin of acid and pepsin secretion in response to histamine stimulation was less marked than its effect on pentagastrin-stimulated acid and pepsin secretion.

Somatostatin inhibits the release of acid, pepsin, and gastrin from parietal, chief, and G-cells in response to a meal, of acid and gastrin in response to insulin, and of acid and pepsin in response to pentagastrin and histamine. The physiological significance of this inhibition remains uncertain. Somatostatin has not been detected in peripheral blood, so that it is unlikely to be a circulating hormone. However, the wide distribution of somatostatin in the alimentary system could allow it a paracrine role as a local chemical regulator of exocrine as well as endocrine secretion.

The support of Pfizer (U.K.) and the Wellcome Trust is gratefully acknowledged.

References
*Lancet, 1*, 1323-1324.
Inhibition by somatostatin (growth-hormone release-inhibiting hormone, GH-RIH) of gastric acid and pepsin and G-cell release of gastrin.

A A Barros D'sa, S R Bloom and J H Baron

Gut 1978 19: 315-320
doi: 10.1136/gut.19.4.315